Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ANPEP | P15144 | 3/20 | 0.31 |
| ▸ | ENPEP | Q07075 | 3/20 | 0.31 |
| ▸ | HMGCR | P04035 | 1/20 | 0.31 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.31 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.31 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.31 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16979290 | 0.79 | RNPEP (0.32) | — | |
| SCHEMBL17719193 | 0.74 | ENPEP (0.37) | ENPEP | |
| SCHEMBL6535498 | 0.74 | PTGS1 (0.35) | — | |
| SCHEMBL17176211 | 0.74 | ENPEP (0.37) | ENPEP | |
| SCHEMBL17674518 | 0.72 | — | — | |
| SCHEMBL12229214 | 0.72 | PTGS1 (0.50) | ANPEPENPEP | |
| SCHEMBL16590594 | 0.72 | PTGS1 (0.50) | ANPEPENPEP | |
| SCHEMBL7455440 | 0.71 | — | — | |
| SCHEMBL5493506 | 0.67 | L3MBTL1 (0.32) | — | |
| SCHEMBL15745110 | 0.67 | KDM4E (0.38) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190144488-A1 | TRITYL-MONO-GalNAc COMPOUNDS AND THEIR USE | ROCHE INNOVATION CENTER COPENHAGEN A/S (DK) | 2019-05-16 | — | — | US | claimed |
| EP-3442983-A1 | TRITYL-MONO-Ga1NAc COMPOUNDS AND THEIR USE | H. Hoffnabb-La Roche Ag (CH) | 2019-02-20 | — | — | EP | claimed |
| US-20170327524-A1 | GALNAC PHOSPHORAMIDITES, NUCLEIC ACID CONJUGATES THEREOF AND THEIR USE | HOFFMANN-LA ROCHE INC. | 2017-11-16 | — | — | US | claimed |
| WO-2017178656-A1 | TRITYL-MONO-GalNAc COMPOUNDS AND THEIR USE | ROCHE INNOVATION CENTER COPENHAGEN A/S (DK) | 2017-10-19 | — | — | WO | claimed |
| EP-3204397-A1 | GALNAC PHOSPHORAMIDITES, NUCLEIC ACID CONJUGATES THEREOF AND THEIR USE | F. Hoffmann-La Roche AG (CH) | 2017-08-16 | — | — | EP | claimed |
| WO-2016055601-A1 | GALNAC PHOSPHORAMIDITES, NUCLEIC ACID CONJUGATES THEREOF AND THEIR USE | F. HOFFMANN-LA ROCHE AG (CH) | 2016-04-14 | — | — | WO | claimed |
| US-11248019-B2 | Trityl-mono-GalNAc compounds and their use | HOFFMANN-LA ROCHE INC. (US) | 2022-02-15 | — | — | US | disclosed |
| US-20210017214-A1 | GALNAC PHOSPHORAMIDITES, NUCLEIC ACID CONJUGATES THEREOF AND THEIR USE | HOFFMANN LA ROCHE (US) | 2021-01-21 | — | — | US | disclosed |
| CN-106795200-B | Galnac phosphoramidites, nucleic acid conjugates thereof, and uses thereof | 豪夫迈·罗氏有限公司 | 2020-06-19 | — | — | CN | disclosed |
| US-20190144488-A1 | TRITYL-MONO-GalNAc COMPOUNDS AND THEIR USE | ROCHE INNOVATION CENTER COPENHAGEN A/S (DK) | 2019-05-16 | — | — | US | disclosed |
| EP-3442983-A1 | TRITYL-MONO-Ga1NAc COMPOUNDS AND THEIR USE | H. Hoffnabb-La Roche Ag (CH) | 2019-02-20 | — | — | EP | disclosed |
| US-20170327524-A1 | GALNAC PHOSPHORAMIDITES, NUCLEIC ACID CONJUGATES THEREOF AND THEIR USE | HOFFMANN-LA ROCHE INC. | 2017-11-16 | — | — | US | disclosed |
| WO-2017178656-A1 | TRITYL-MONO-GalNAc COMPOUNDS AND THEIR USE | ROCHE INNOVATION CENTER COPENHAGEN A/S (DK) | 2017-10-19 | — | — | WO | disclosed |
| EP-3204397-A1 | GALNAC PHOSPHORAMIDITES, NUCLEIC ACID CONJUGATES THEREOF AND THEIR USE | F. Hoffmann-La Roche AG (CH) | 2017-08-16 | — | — | EP | disclosed |
| WO-2016055601-A1 | GALNAC PHOSPHORAMIDITES, NUCLEIC ACID CONJUGATES THEREOF AND THEIR USE | F. HOFFMANN-LA ROCHE AG (CH) | 2016-04-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11248019-B2 | Trityl-mono-GalNAc compounds and their use | FUT6, GALNT1, FUT5 | ANPEP 525/4885ENPEP 401/4885HMGCR 2652/4885 |
| US-20190144488-A1 | TRITYL-MONO-GalNAc COMPOUNDS AND THEIR USE | FUT6, GALNT1, FUT5 | ANPEP 525/4885ENPEP 401/4885HMGCR 2652/4885 |
| US-20210017214-A1 | GALNAC PHOSPHORAMIDITES, NUCLEIC ACID CONJUGATES THEREOF AND THEIR USE | FUT6, FUT5, GALNT6 | ANPEP 196/4885ENPEP 155/4885HMGCR 3095/4885 |
| US-20170327524-A1 | GALNAC PHOSPHORAMIDITES, NUCLEIC ACID CONJUGATES THEREOF AND THEIR USE | FUT6, FUT5, GALNT6 | ANPEP 196/4885ENPEP 155/4885HMGCR 3095/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.